The main purpose of Evista is to prevent and treat osteoporosis. Moreover, in the EU, the drug is prescribed as a means of combating osteoporosis in postmenopausal women.
During the studies, it was noted that the drug significantly reduces the risk of fractures in the spine, but not in the hip.
Raloxifene (Evista) is a selective estrogen receptor modulator (SERM) that helps reduce the risk of breast cancer by acting on hormone receptors in women with a higher than average risk of developing breast cancer.
Raloxifene acts as an agonist (blocker) of the estrogen receptor in bone and some body tissues. Raloxifene does not affect estrogen in the uterus and does not increase the risk of cancer in this organ.
Raloxifene has been studied in 4 international studies on the prevention and treatment of osteoporosis, including a total of 10,000 women.
The results of a study on the prevention of osteoporosis showed that in the group of women taking Evista for 2 years, there was an increase in bone density of the spine and hip by 1.6%, while in the placebo group there was a decrease in density by 0.8%.
In the treatment of osteoporosis, Raloxifene was more effective than placebo in reducing the incidence of vertebral fractures by 46%. However, there was no reduction in the incidence of hip fractures.
In a study testing the effectiveness of Raloxifene as a drug to reduce the risk of invasive breast cancer among postmenopausal women with an increased risk, it was noted that after 4 years of taking the drug, the risk of invasive breast cancer was reduced by 60-70% in the groups taking Raloxifene, compared with placebo.
Купить Evista
Цена Evista
Buy Evista
Price Evista
